C4 Therapeutics Inc (CCCC)

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

C4 Therapeutics to Participate in Upcoming Conferences

WATERTOWN, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a...

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

WATERTOWN, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a...

Form 8-K - Current report

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

C4 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights

Progressed Plans to Establish Cemsidomide as a Potentially Foundational Treatment for Multiple Myeloma;...

Form ARS - Annual Report to Security Holders

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form DEF 14A - Other definitive proxy statements

Form 8-K - Current report

Form 8-K - Current report